Takeda Pharmaceutical (TAK) Shares Gap Down to $17.92

Share on StockTwits

Takeda Pharmaceutical Co Ltd (NYSE:TAK) shares gapped down prior to trading on Wednesday . The stock had previously closed at $16.84, but opened at $17.92. Takeda Pharmaceutical shares last traded at $17.93, with a volume of 73857 shares changing hands.

TAK has been the subject of a number of analyst reports. Zacks Investment Research raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a report on Wednesday, March 13th. Goldman Sachs Group reissued a “buy” rating on shares of Takeda Pharmaceutical in a report on Tuesday, March 19th.

The firm has a market cap of $30.45 billion, a PE ratio of 16.85, a P/E/G ratio of 67.18 and a beta of 0.66. The company has a debt-to-equity ratio of 1.19, a current ratio of 3.06 and a quick ratio of 2.81.

A number of large investors have recently made changes to their positions in the business. Adelphi Capital LLP acquired a new position in shares of Takeda Pharmaceutical during the 1st quarter worth approximately $188,841,000. Northern Trust Corp raised its stake in shares of Takeda Pharmaceutical by 23.5% during the 1st quarter. Northern Trust Corp now owns 4,218,850 shares of the company’s stock worth $85,939,000 after buying an additional 803,851 shares during the period. Parametric Portfolio Associates LLC raised its stake in shares of Takeda Pharmaceutical by 114.9% during the 1st quarter. Parametric Portfolio Associates LLC now owns 3,312,996 shares of the company’s stock worth $67,486,000 after buying an additional 1,771,039 shares during the period. Mondrian Investment Partners LTD raised its stake in shares of Takeda Pharmaceutical by 4.8% during the 1st quarter. Mondrian Investment Partners LTD now owns 3,012,870 shares of the company’s stock worth $60,257,000 after buying an additional 139,000 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Takeda Pharmaceutical during the 1st quarter worth approximately $60,381,000. 4.42% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Takeda Pharmaceutical (TAK) Shares Gap Down to $17.92” was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://weekherald.com/2019/05/15/takeda-pharmaceutical-tak-shares-gap-down-to-17-92.html.

About Takeda Pharmaceutical (NYSE:TAK)

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Featured Story: What does a bar chart mean for investors?

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.